Should aspirin (acetylsalicylic acid) and apixaban (Eliquis) be given after abdominal aortic aneurysm repair?

Aspirin After AAA Repair: Yes, Unless Contraindicated; Apixaban: Only If Specific Indication Exists

After AAA repair, aspirin 75-100 mg daily should be given for secondary prevention of cardiovascular events, as AAA is considered a coronary artery disease equivalent. Apixaban (Eliquis) should only be given if there is a separate indication for anticoagulation (such as atrial fibrillation or venous thromboembolism), not routinely for AAA repair itself.

Aspirin Therapy Post-AAA Repair

The 2022 ACC/AHA Aortic Disease Guidelines provide a Class 2b recommendation that in patients with AAA with concomitant atheroma and/or penetrating atherosclerotic ulcer, low-dose aspirin (75-162 mg) may be considered unless contraindicated 1. This reflects that:

• AAA patients have a >20% risk of cardiovascular events within 10 years, making them coronary artery disease equivalents
• Aspirin 75-162 mg daily for secondary prevention is incorporated into standard atherosclerotic vascular disease management
• The evidence is limited and somewhat conflicting regarding AAA-specific outcomes

Important Caveats About Aspirin

Recent research raises concerns about aspirin in certain AAA populations:

• A 2024 Chinese study found that long-term aspirin after EVAR was associated with higher rates of aneurysm sac enlargement and persistent type II endoleaks compared to no aspirin 2
• A 2025 Korean nationwide study showed no cardiovascular or procedural benefit from dual antiplatelet therapy (DAPT) versus single antiplatelet therapy after EVAR, with DAPT increasing bleeding risk 3
• A 2025 study found aspirin may be associated with increased AAA progression specifically in females with small aneurysms (<50 mm) 4

Despite these concerns, the cardiovascular risk reduction benefits generally outweigh AAA-specific concerns, particularly given that cardiovascular events remain the leading cause of death in AAA patients.

Apixaban (Eliquis) After AAA Repair

Apixaban should NOT be given routinely after AAA repair. It should only be prescribed if there is a separate, established indication for anticoagulation:

Specific Indications for Apixaban:

1. Atrial Fibrillation: Standard dose is 5 mg twice daily (or 2.5 mg twice daily if patient meets dose reduction criteria: age ≥80, weight ≤60 kg, or creatinine ≥1.5 mg/dL) 5

2. Venous Thromboembolism: Initial treatment dose is 10 mg twice daily for 7 days, then 5 mg twice daily 5

3. Other established anticoagulation indications (mechanical heart valves are contraindicated for DOACs)

Combining Aspirin and Apixaban

If both aspirin and apixaban are indicated (e.g., AAA patient with atrial fibrillation):

• After the immediate post-operative period, anticoagulation alone is generally preferred over combination therapy to minimize bleeding risk 6
• The 2024 ESC Guidelines state that in patients with a long-term indication for oral anticoagulation, a therapeutic dose of DOAC (like apixaban) alone is recommended lifelong 6
• Combination therapy (aspirin + anticoagulation) increases bleeding risk significantly without clear additional benefit in most scenarios 7

Research Evidence on Anticoagulation Post-EVAR

Anticoagulation after EVAR has concerning associations:

• A 2022 study found that long-term anticoagulation plus aspirin was associated with decreased AAA sac regression (41.6% vs 58.4%) and increased type II endoleaks (12% vs 6.3%) compared to aspirin alone 8
• A 2025 study showed anticoagulant use was a significant predictor of prosthetic limb occlusion (HR 3.79) after EVAR 9

Practical Algorithm

For AAA repair patients:

1. Start aspirin 75-100 mg daily unless contraindicated (active bleeding, severe bleeding disorder, aspirin allergy)

2. Assess for anticoagulation indications:

   • If atrial fibrillation, VTE, or other established indication → Start appropriate anticoagulation
   • If anticoagulation indicated → Stop aspirin and use anticoagulation alone after immediate post-operative period
   • If no anticoagulation indication → Continue aspirin monotherapy

3. Monitor for:

   • Bleeding complications (especially GI bleeding - consider PPI if high risk)
   • Cardiovascular events
   • AAA sac changes on surveillance imaging
   • In females with small aneurysms, consider more frequent surveillance if on aspirin

4. Perioperative management:

   • For elective AAA repair, discontinue apixaban 3 days before surgery 10
   • Restart anticoagulation when adequate hemostasis established (typically 24-48 hours post-op) 5
   • Aspirin can typically be continued perioperatively for vascular surgery 11

The key principle: Treat the cardiovascular disease risk (aspirin), only add anticoagulation if there's a separate compelling indication, and avoid unnecessary combination therapy that increases bleeding without proven benefit in this population.